Mitocin (Mitomycin)

Mitomycin is a bioreductive alkylating agent. Inside hypoxic tumour cells it is reduced to a reactive intermediate that creates covalent cross‑links between DNA strands. These cross‑links block DNA replication and transcription, causing cell‑cycle arrest and ultimately leading to apoptosis of rapidly dividing cancer cells.

The dose of Mitocin is individualized by the treating oncologist based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and the intended route of administration (intravenous or intravesical). Only a qualified prescriber can determine the appropriate regimen.

Mitocin is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and women of child‑bearing potential must use effective contraception. Safety during breastfeeding has not been established, so breastfeeding is generally discouraged while receiving the drug.

To request Mitocin, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and assistance with import documentation.

Compared with older alkylating agents such as cyclophosphamide, Mitocin has a distinct bioreductive activation that preferentially targets hypoxic tumour cells, potentially offering greater efficacy in certain solid tumours. However, its toxicity profile includes a higher risk of haemorrhagic cystitis when used intravesically, requiring specific monitoring and preventive measures.

Mitocin should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and prevent contamination.

Mitocin is supplied as a sterile solution for injection. It can be given intravenously as an infusion under the supervision of a qualified healthcare professional, or it may be instilled directly into the bladder (intravesical) after tumour resection, following the specific protocol prescribed by the oncologist.

Serious adverse events include haemorrhagic cystitis, severe bone‑marrow suppression leading to aplastic anemia or pancytopenia, pulmonary toxicity such as interstitial pneumonitis, and acute renal impairment. Patients should be monitored closely for signs of bleeding, infection, respiratory distress and changes in kidney function.

Mitocin is contraindicated in pregnant women, patients with known hypersensitivity to mitomycin or any component of the formulation, and individuals with severe renal or hepatic impairment where dose adjustment is not feasible. Caution is also advised for patients receiving concurrent radiation therapy or other myelosuppressive agents.